Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer

Lee, Maria; Kim, Eun Jae; Cho, Youngnam; Kim, Sunshin; Chung, Hyun Hoon; Park, Noh Hyun; Song, Yong Sang

doi:10.1016/j.ygyno.2017.02.042

Cited by 82 publications

(67 citation statements)

References 20 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The link between CTC clusters and resistance to treatments is becoming more and more obvious. Lee et al reported platinium resistance in primary or recurrent ovarian cancer associated with the presence of CTC clusters in peripheral blood [55]. Although not explained by the authors, the study highlights a correlation between CTC clusters and metastatic evolution.…”

Section: Towards Innovative Treatment Leveragementioning

confidence: 59%

Circulating Tumor Cell Clusters: United We Stand Divided We Fall

Amintas

Bedel

Moreau‐Gaudry

et al. 2020

IJMS

View full text Add to dashboard Cite

The presence of circulating tumor cells (CTCs) and CTC clusters, also known as tumor microemboli, in biological fluids has long been described. Intensive research on single CTCs has made a significant contribution in understanding tumor invasion, metastasis tropism, and intra-tumor heterogeneity. Moreover, their being minimally invasive biomarkers has positioned them for diagnosis, prognosis, and recurrence monitoring tools. Initially, CTC clusters were out of focus, but major recent advances in the knowledge of their biogenesis and dissemination reposition them as critical actors in the pathophysiology of cancer, especially metastasis. Increasing evidence suggests that “united” CTCs, organized in clusters, resist better and carry stronger metastatic capacities than “divided” single CTCs. This review gathers recent insight on CTC cluster origin and dissemination. We will focus on their distinct molecular package necessary to resist multiple cell deaths that all circulating cells normally face. We will describe the molecular basis of their increased metastatic potential as compared to single CTCs. We will consider their clinical relevance as prognostic biomarkers. Finally, we will propose future directions for research and clinical applications in this promising topic in cancer.

show abstract

Section: Towards Innovative Treatment Leveragementioning

confidence: 59%

Circulating Tumor Cell Clusters: United We Stand Divided We Fall

Amintas

Bedel

Moreau‐Gaudry

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…While CTM detection at baseline generally indicated a lower PFS, persistence or appearance of CTM after therapy indicated reduced PFS highlighting the prognostic potential of CTM (Fanelli et al, 2017). Furthermore, it has been shown that in NSCLC patients CTM prevalence is correlated with stage of the disease whilst presence of CTM was correlated with resistance to therapy in epithelial ovarian cancer (EOC) patients (Lee et al, 2017). Taken together, these investigations suggest the potential for CTM as diagnostic, prognostic, and predictive biomarker.…”

Section: Ctm In Clinic: Diagnostic Prognostic and Predictive Potentialmentioning

confidence: 94%

Circulating tumor microemboli: Progress in molecular understanding and enrichment technologies

Umer

Vaidyanathan

Nguyen

et al. 2018

Biotechnology Advances

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) and their clusters, also known as circulating tumor microemboli (CTM), have emerged as valuable tool that can provide mechanistic insights into the tumor heterogeneity, clonal evolution, and stochastic events within the metastatic cascade. However, recent investigations have hinted that CTM may not be mere aggregates of tumor cells but cells comprising CTM exhibit distinct phenotypic and molecular characteristics in comparison to single CTCs. Moreover, in many cases CTM demonstrated higher metastatic potential and resistance to apoptosis as compared to their single cell counterparts. Thus, their evaluation and enumeration may provide a new dimension to our understanding of cancer biology and metastatic cancer spread as well as offer novel theranostic biomarkers. Most of the existing technologies for isolation of hematogenous tumor cells largely favor single CTCs, hence there is a need to devise new approaches, or re-configure the existing ones, for specific and efficient CTM isolation. Here we review existing knowledge and insights on CTM biology. Furthermore, a critical commentary on current and emerging trends in CTM enrichment and characterization along with recently developed ex-vivo CTC expansion methodologies is presented with the aim to facilitate researchers to identify further avenues of research and development.

show abstract

“…Based on the precipitation of CTCs in the low-speed centrifuge, the leukocyte fractions can be distinguished via physical features as well. Lee et al used a nanoroughened microfluidic platform and detected CTCs in the sera of nearly all female participants (53/54, 98.1%) with ovarian cancer [12]. They also showed that although there is no relationship between CTC count and PFS in patients with newly diagnosed epithelial ovarian cancer (EOC), in patients with recurrent disease and chemoresistance; a relationship was found between CTC-cluster positivity and diminished OS [12].…”

Section: Circulating Tumor Cells (Ctcs)mentioning

confidence: 99%

“…Lee et al used a nanoroughened microfluidic platform and detected CTCs in the sera of nearly all female participants (53/54, 98.1%) with ovarian cancer [12]. They also showed that although there is no relationship between CTC count and PFS in patients with newly diagnosed epithelial ovarian cancer (EOC), in patients with recurrent disease and chemoresistance; a relationship was found between CTC-cluster positivity and diminished OS [12]. It has been postulated that CTCs could result in metastatic progression and recurrence by way of epithelial-mesenchymal-transition (EMT) or development of stem-like features and hence a reduced OS.…”

Section: Circulating Tumor Cells (Ctcs)mentioning

confidence: 99%

The Role of Circulating Biomarkers in the Early Diagnosis of Ovarian Cancer

Gumusoglu‐Acar¹,

Günel²

2018

Ovarian Cancer - From Pathogenesis to Treatment

View full text Add to dashboard Cite

Ovarian cancer is the leading cause of gynecologic-related cancer death and epithelial ovarian cancer (EOC) is the most lethal sub-type. EOC is usually asymptomatic, and few screening tests are available. Diagnosis of ovarian cancer can be difficult because of the nonspecific symptoms. Despite the various diagnostic methods used, there is no reliable early diagnostic test and it needs to be developed. Specific biomarkers may have potential with the least possible invasive procedure. Biomarkers with a high sensitivity to ovarian cancer should be identified. Circulating biomarkers that are significant tools for non-invasive early diagnosis can be analyzed using circulating tumor cells, exosomes, and circulating nucleic acids. Protein, gene, metabolite, and miRNA-based biomarkers can be used for ovarian cancer diagnosis. As non-coding RNAs, MiRNAs may have an important role in ovarian cancer diagnosis due to their effects on mRNA expression levels. The most recent developments regarding the potential of circulating biomarkers to detect early ovarian cancer is presented in this chapter.

show abstract

Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer

Abstract: Proof-of-concept was provided for an electrically conductive and nanoroughened microfluidic platform-based chip designed to capture CTCs in patients with EOC. A larger patient sampling and longer duration of follow-up are needed to determine its suitability for clinical use.

Cited by 82 publications

References 20 publications

Circulating Tumor Cell Clusters: United We Stand Divided We Fall

Circulating Tumor Cell Clusters: United We Stand Divided We Fall

Circulating tumor microemboli: Progress in molecular understanding and enrichment technologies

The Role of Circulating Biomarkers in the Early Diagnosis of Ovarian Cancer

Contact Info

Product

Resources

About